Joshua Boger, President and CEO of Vertex Pharmaceuticals Incorporated and chairman of BIO’s board of directors, discusses the importance of advocating for policies and actions that will support the innovation economy where biotech companies play such a critical role.
Rachel King, CEO of GlycoMimetics of Gaithersburg, Md, testified on behalf of BIO. In her prepared remarks, King told the subcommittee, "Of course, one way to both spur the economy and provide support for biomedical research is increasing federal funding of the National Institutes of Health (NIH)."
BIO sent a letter to SEC Chairman Christopher Cox and SEC Director Linda Thomsen in September commending the agency for its efforts to investigate fraud and crack down on activities such as rumor mongering and abusive naked short selling in capital markets.
An opportunity to better understand how to comply with federal requirements for regulated field trials - a focus on corn, cotton and soy.
Sign up for the course
In these trying economic times, biotech entrepreneurs are being put to the test to not only raise capital, but just to survive. Start-ups that a year or two ago would have been flush with capital from several sources, have been forced to closely monitor their burn rates and conserve capital through a new-found mindset of frugality.
Policy Updates
Small Business Innovation Research Grants (SBIR)
Not sure what the SBIR issue is? Check out our Hopes and Cures Blog, and find out why stamping out SBIR will also stamp out hope for cures.
